HALO stock forecast, quote, news & analysis
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies... Show more
Halozyme Therapeutics (HALO) Stock Analysis: ENHANZE Royalty Engine Powers Multi-Year Growth Narrative
Key Takeaways
- Halozyme Therapeutics shares have gained approximately 9.3% over the past 30 days, trading near $81.93 and approaching their 52-week high of $82.99.
- First-quarter 2026 earnings beat Wall Street expectations, with EPS of $1.60 on revenue of $376.7 million, representing 42.2% year-over-year revenue growth driven by ENHANZE royalties.
- The company reaffirmed full-year 2026 guidance calling for $7.75–$8.25 in non-GAAP EPS and total revenue between $1.71 billion and $1.81 billion.
- Halozyme signed three new collaboration agreements in 2026, including deals with GSK, Incyte, and Vertex Pharmaceuticals, expanding the ENHANZE and Hypercon technology portfolios.
- Institutional ownership stands at approximately 97.8%, while analysts maintain a consensus Moderate Buy rating with an average price target of $81.60.
- A $1 billion share repurchase authorization, with at least $400 million expected in 2026, underscores management's commitment to returning capital to shareholders.
Current Market Snapshot
Halozyme Therapeutics (NASDAQ: HALO) closed at $81.93 on July 24, 2026, capping a steady climb from the mid-$60s range in late April. The stock has gained roughly 9.3% over the past 30 days and approximately 25% over the last quarter, reflecting growing investor confidence in the company's royalty-driven business model. With a market capitalization near $9.72 billion, a price-to-earnings ratio of approximately 29.5, and a beta of 0.84, HALO has shown relatively lower volatility compared to the broader biotech sector. The stock's 50-day moving average of $73.08 and 200-day moving average of $70.58 both sit well below current levels, indicating sustained upward momentum. Institutional investors control roughly 97.8% of outstanding shares, underscoring strong professional ownership interest.
Halozyme Therapeutics (HALO) Business Overview and Competitive Position
Halozyme Therapeutics is a San Diego-based biopharmaceutical company specializing in novel drug-delivery technologies. Its flagship ENHANZE platform, built on the proprietary enzyme rHuPH20, enables subcutaneous administration of biologic therapies that would otherwise require intravenous infusion. ENHANZE underpins ten approved products across more than 100 global markets, including blockbuster therapies such as DARZALEX FASPRO, VYVGART Hytrulo, and Phesgo. The company licenses its technology to major pharmaceutical partners including Roche, Johnson & Johnson, Pfizer, AbbVie, Eli Lilly, and Bristol-Myers Squibb, collecting mid-single-digit royalties on partner product sales. Halozyme has expanded its portfolio through the acquisitions of Hypercon and Surf Bio, adding hyperconcentration technologies that broaden the range of biologics addressable through subcutaneous delivery. The company also manufactures auto-injector drug-device combination products and markets proprietary products including Hylenex and XYOSTED.
Recent Developments Driving HALO
Several catalysts have shaped Halozyme's stock profile in recent weeks. On July 20, the company announced a global collaboration with Incyte to apply ENHANZE technology to INCA033989, a first-in-class monoclonal antibody targeting mutant calreticulin in myeloproliferative neoplasms, with an option for up to two additional targets. The deal followed a May 2026 agreement with GSK covering multiple oncology targets including antibody-drug conjugates, marking ENHANZE's first foray into that modality.
On June 15, Halozyme confirmed that the CMS draft Medicare Drug Price Negotiation Program proposed rule projects zero to minimal impact on royalty revenue through at least 2035, removing a key regulatory overhang that had concerned some investors. The company's first-quarter earnings report on May 11 further reinforced the growth narrative: royalty revenue surged 43% year-over-year to $240.7 million, driven by strong commercial performance of DARZALEX, VYVGART Hytrulo, and newer launches including subcutaneous OCREVUS and Opdivo. Management also announced a new $1 billion share repurchase program. Analyst sentiment remains broadly favorable, with firms including UBS, Benchmark, Morgan Stanley, and HC Wainwright maintaining Buy-equivalent ratings, though some institutional holders such as Arrowstreet Capital and Candriam reduced positions in recent quarters. Insider selling by CEO Helen Torley and Director Mahesh Krishnan was executed under pre-arranged Rule 10b5-1 trading plans.
Trending AI Robots
For investors seeking data-driven approaches to navigate stocks like Halozyme Therapeutics, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across diverse strategies and timeframes. However, only the most consistently relevant and highest-performing bots are featured in the Trending section, making it a streamlined entry point for traders who want to monitor real-time AI-driven signals without manually sifting through the full bot marketplace. Each bot differs in its strategic approach, holding period, and key performance metrics, allowing users to identify signals aligned with their own trading style. Exploring this page can help investors stay informed about emerging algorithmic sentiment and momentum patterns across a broad range of stocks.
2026 Outlook and What Investors Should Watch
Halozyme's trajectory in the second half of 2026 hinges on several key factors. Royalty revenue growth remains the primary engine, with management projecting ENHANZE royalties to exceed $1 billion for the first time this year. Investors will closely monitor quarterly product-level royalty trends, particularly for DARZALEX, VYVGART Hytrulo, and the subcutaneous OCREVUS ramp. The company's capital allocation strategy — balancing organic investment in Hypercon and Surf Bio with the $1 billion buyback program — will also influence shareholder returns and EPS growth. Upcoming milestones include potential additional ENHANZE and Hypercon licensing deals beyond the three already signed in 2026, as well as clinical progress from partner pipeline programs. On the regulatory front, the final CMS rule on Medicare drug price negotiation and ongoing patent litigation with Merck bear monitoring. With the stock trading near its 52-week high and analyst price targets clustered near current levels, upcoming earnings releases will be critical in validating the premium valuation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HALO's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for HALO turned positive on July 24, 2026. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 23, 2026. You may want to consider a long position or call options on HALO as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 50-day moving average for HALO moved above the 200-day moving average on July 06, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 321 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 290 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for HALO moved out of overbought territory on July 31, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HALO broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (44.643) is normal, around the industry mean (19.620). P/E Ratio (28.961) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (6.729) is also within normal values, averaging (420.906).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology